-
In 2025, digital transformation stopped being a corporate buzzword and became a measurable survival strategy. Across industries, organisations discovered that adopting technology alone was not enough. Instead, success depended on how deeply digital systems reshaped operations, decision-making, and customer engagement. As businesses move further into an AI-driven economy, the lessons learned from 2025 are now…
-
Artificial intelligence promised objectivity. Instead, it inherited our blind spots. Across industries—from healthcare and hiring to finance and criminal justice—predictive systems shape who gets loans, who receives medical care faster, and even who gets flagged as a risk. Yet despite advances in machine learning, AI bias and algorithmic fairness remain stubborn, systemic challenges. The uncomfortable…
-
The question is no longer whether humans can enhance themselves. It’s whether we should—and under what rules. From gene editing and neural implants to AI-augmented cognition and bioengineered longevity, human enhancement technologies are accelerating. What once belonged to speculative fiction now occupies boardrooms, biotech labs, and policy debates. Yet innovation without ethical structure rarely ends…
-
A decade ago, bioinformatics sat quietly inside research labs. Today, it sits at the centre of biotech strategy, pharmaceutical R&D, genomic medicine, and even AI-driven healthcare startups. In 2026, biology no longer moves forward without code. Bioinformatics—the discipline that merges biology, data science, and computational modelling—has evolved from a niche academic speciality into a core…
-
For over a century, industrial growth has depended on fossil fuels and petrochemicals. Plastic, fuel, textiles, packaging—modern civilisation runs on carbon extracted from the ground. However, a new shift is underway. Instead of drilling for hydrocarbons, scientists are programming living cells to manufacture them. Synthetic biology is rapidly evolving from laboratory curiosity into industrial infrastructure.…
-
For decades, gene therapy lived on the edge of possibility. Scientists promised cures at the molecular level. Investors poured billions into biotech startups. Yet progress often felt incremental—punctuated by setbacks, safety concerns, and regulatory hesitation. Then, 2026 changed the tempo. This year marks a structural shift in how gene therapy is developed, delivered, and scaled.…
-
A tiny chip beneath the skin.A neural implant translating thoughts into movement.A cardiac device transmitting data to the cloud in real time. What once felt speculative now exists inside operating rooms—and increasingly, inside people. Implantable technology is advancing at a pace few predicted. Yet as these devices move from life-saving tools to lifestyle enhancements, one…
-
If you had told a surgeon twenty years ago that they could operate on a patient thousands of miles away, they would have called it science fiction. Today, it’s clinical reality. Remote surgery and robotic assistance are no longer experimental side projects inside elite research labs. Instead, they are rapidly becoming pillars of modern healthcare…
-
For most of the modern era, biotechnology and digital technology evolved in parallel. One decoded life. The other digitised information. However, that separation is rapidly dissolving. Today, DNA is treated like code. Cells are engineered like programmable systems. Drug discovery is accelerated by artificial intelligence. Biological data is processed in cloud-scale environments. In short, biotechnology…
-
Artificial intelligence is everywhere. From generative chatbots to predictive healthcare systems, AI appears unstoppable. Companies invest billions. Governments race for dominance. Headlines promise transformation across every industry. However, beneath the excitement lies a quieter reality. Artificial intelligence has limits—technical, economic, ethical, and structural—that are rarely discussed with the same enthusiasm as breakthroughs. Understanding these limits…